Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 106 citing articles:

Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England
Freja Kirsebom, Katie Harman, Rachel Lunt, et al.
The Lancet Regional Health - Europe (2023) Vol. 35, pp. 100755-100755
Open Access | Times Cited: 20
Covid-19 Vaccine Hesitancy and Under-Vaccination among Marginalized Populations in the United States and Canada: A Scoping Review
Peter A. Newman, Duy A Dinh, Thabani Nyoni, et al.
Journal of Racial and Ethnic Health Disparities (2023)
Open Access | Times Cited: 19
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Shanti Pather, Alexander Muik, Ruben Rizzi, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 650-661
Open Access | Times Cited: 16
Relative effectiveness of bivalent COVID-19 vaccine: a systematic review and meta-analysis
Meng-qun Cheng, Rong Li, Zhiying Weng, et al.
Frontiers in Medicine (2024) Vol. 10
Open Access | Times Cited: 5
A framework for monitoring RSV prevention product effectiveness in the United States
Lauren E. Roper, Ruth Link‐Gelles, Diya Surie, et al.
Vaccine (2025) Vol. 45, pp. 126633-126633
Closed Access
Multidimensional Demographic Analyses of COVID-19 Vaccine Inequality in the United States: A Systematic Review
Seyed M. Karimi, Sirajum Munira Khan, Mana Moghadami, et al.
Healthcare (2025) Vol. 13, Iss. 2, pp. 139-139
Open Access
Optimizing vaccination campaign strategies considering societal characteristics
Serin Lee, Zelda B. Zabinsky, Shan Liu
Health Care Management Science (2025)
Closed Access
Morris responds to “Critical analyses concerning COVID-19 vaccines need to be consistently critical, and informed”
Jeffrey S. Morris
American Journal of Epidemiology (2025)
Closed Access
Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy
Abby E. Rudolph, Farid Khan, Amy Shah, et al.
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 3, pp. 648-659
Open Access | Times Cited: 15
Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023
Nathaniel M. Lewis, Yuwei Zhu, Ithan D. Peltan, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 4, pp. 1056-1064
Open Access | Times Cited: 15
COVID-19 Vaccination in Korea
Wan Beom Park, Young Hoon Hwang, Hee Jin Cheong
Infection and Chemotherapy (2023) Vol. 55, Iss. 1, pp. 135-135
Open Access | Times Cited: 14
Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – March 2023
Eero Poukka, Hanna Nohynek, Sirkka Goebeler, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 13
Durability of protection from original monovalent and bivalent COVID-19 vaccines against COVID-19-associated hospitalization and severe in-hospital outcomes among adults in the United States — September 2022–August 2023
Jennifer DeCuir, Diya Surie, Yuwei Zhu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children
Frances Priddy, Spyros Chalkias, Brandon Essink, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 862-878
Open Access | Times Cited: 4
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Masayuki Amano, Sachiko Otsu, Yukari Uemura, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods
Allison Avrich Ciesla, Ryan E. Wiegand, Zachary Smith, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 10
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
Louise Murdoch, Karen Quan, James A. Baber, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 9, pp. 2241-2258
Open Access | Times Cited: 10
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
Asghar Abdoli, Hamidreza Jamshidi, Mohammad Taqavian, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273
Ivan T. Lee, Catherine A. Cosgrove, Patrick Moore, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 9
Hybrid Immunity Provides Protective Advantage Over Vaccination or Prior Remote Coronavirus Disease 2019 Alone
Abinash Virk, Matthew G. Johnson, Daniel Roellinger, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 9
Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan
Takeshi Arashiro, Yuzo Arima, Jin Kuramochi, et al.
Open Forum Infectious Diseases (2023)
Open Access | Times Cited: 9
COVID-19
Kristen Marks, Roy M. Gulick
Annals of Internal Medicine (2023) Vol. 176, Iss. 10, pp. ITC145-ITC160
Closed Access | Times Cited: 9
Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022–May 2023
Ian D. Plumb, Melissa Briggs Hagen, Ryan E. Wiegand, et al.
Vaccine (2023) Vol. 42, Iss. 10, pp. 2543-2552
Open Access | Times Cited: 9
“Going vaccine hunting” : Multilevel influences on COVID-19 vaccination among racialized sexual and gender minority adults—a qualitative study
Peter A. Newman, Duy A Dinh, Notisha Massaquoi, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3
Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States
Manuela Di Fusco, Kinga Marczell, Elizabeth Thoburn, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 509-524
Open Access | Times Cited: 8

Scroll to top